NRTI might have the right approach in this MJ thing. It looks to me that they are going for some high-end product with a clear benefit for users and high credentials (through the scientific board). They will probably end up with some niche product, but one with very high profit margins - leaving most of the companies in this overhyped MJ sector far behind.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.